HIKMA PHARMACEUTICALS PLC ORD SHS 10P chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 11.14
Dividend & Yield0.42£ (3.36%)
Beta 0.16
Market capitalization 2.72B
Operating cash flow 583M
ESG Scores 29.2

Company description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.38
Working Capital0.39
Return On Equity0.17
Debt To Equity0.27
Fixed Asset Ratio0.18
Fixed Interest Cover13.05

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 88M -6M 6M 14M
Total Cashflows From Investing Activities -96M -151M -283M -238M
Net Borrowings -141M -10M 220M -114M
Total Cash From Financing Activities -278M -155M -298M -287M
Change To Operating Activities -21M -34M 13M 84M
Issuance Of Stock
Net Income 282M 486M 431M 421M
Change In Cash 49M 166M -119M 103M
Effect Of Exchange Rate -7M -2M -2M -10M
Total Cash From Operating Activities 430M 472M 464M 638M
Depreciation 99M 107M 125M 169M
Change To Account Receivables -41M 21M -47M -166M
Other Cashflows From Financing Activities -53M -48M -34M -53M
Change To Netincome 64M -87M 106M 67M
Capital Expenditures -107M -119M -172M -145M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 118M 126M 137M 143M
Income Before Tax 293M 491M 558M 544M
Net Income 282M 486M 431M 421M
Selling General Administrative 467M 487M 506M 561M
Gross Profit 1B 1.1B 1.21B 1.3B
Ebit 428M 486M 540M 561M
Operating Income 428M 486M 540M 561M
Interest Expense -41M -36M -41M -43M
Income Tax Expense 8M 4M 128M 124M
Total Revenue 2.07B 2.21B 2.34B 2.55B
Cost Of Revenue 1.07B 1.11B 1.13B 1.25B
Total Other Income ExpenseNet -135M 5M 18M -17M
Net Income From Continuing Ops 285M 487M 430M 420M
Net Income Applicable To Common Shares 282M 486M 431M 421M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.8B 1.8B 1.99B 1.91B
Total Stockholder Equity 1.69B 2.12B 2.13B 2.45B
Other Current Liabilities 275M 350M 304M 328M
Total Assets 3.5B 3.93B 4.13B 4.37B
Common Stock 40M 41M 41M 42M
Other Current Assets 41M 19M 26M 8M
Retained Earnings 1.58B 1.97B 1.89B 2.19B
Treasury Stock -217M -179M -80M -60M
Cash 276M 442M 323M 426M
Total Current Liabilities 893M 1.47B 1.03B 1.02B
Other Stockholder Equity -216M -178M -80M -60M
Property, Plant, and Equipment 870M 962M 1.07B 1.15B
Total Current Assets 1.67B 1.85B 1.92B 2.09B
Net Tangible Assets 919M 1.28B 1.26B 1.56B
Net Receivables 745M 747M 736M 876M
Accounts Payable 263M 286M 279M 262M


Insider Transactions

Here are the insider transactions of stock shares related to HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BlackRock Inc.D2022-10-036.32k
BlackRock Inc.D2022-09-3012.48k
Hikma Pharmaceuticals PLCD2022-09-30
Hikma Pharmaceuticals PLCD2022-08-31
Hikma Pharmaceuticals PLCD2022-08-01
Hikma Pharmaceuticals PLCD2022-06-30
Hikma Pharmaceuticals PLCBuy Back at price 19.60 per share.D2022-06-10137.65k
Hikma Pharmaceuticals PLCBuy Back at price 20.13 per share.D2022-06-09150.96k
Hikma Pharmaceuticals PLCBuy Back at price 20.73 per share.D2022-06-08147.32k
Hikma Pharmaceuticals PLCBuy Back at price 20.86 per share.D2022-06-07162.64k
Hikma Pharmaceuticals PLCBuy Back at price 21.06 per share.D2022-06-06184.19k
Hikma Pharmaceuticals PLCBuy Back at price 21.17 per share.D2022-06-01167.42k
Hikma Pharmaceuticals PLCBuy Back at price 21.51 per share.D2022-05-31135.26k
Hikma Pharmaceuticals PLCBuy Back at price 21.50 per share.D2022-05-30157.64k
Hikma Pharmaceuticals PLCBuy Back at price 21.46 per share.D2022-05-27122.64k
Hikma Pharmaceuticals PLCBuy Back at price 21.13 per share.D2022-05-25377.62k
Hikma Pharmaceuticals PLCBuy Back at price 22.07 per share.D2022-05-2384.78k
Hikma Pharmaceuticals PLCBuy Back at price 21.64 per share.D2022-05-20223.22k
Hikma Pharmaceuticals PLCBuy Back at price 21.07 per share.D2022-05-19366.64k
Hikma Pharmaceuticals PLCBuy Back at price 21.05 per share.D2022-05-18216.44k
Hikma Pharmaceuticals PLCBuy Back at price 21.41 per share.D2022-05-17352.89k
Hikma Pharmaceuticals PLCBuy Back at price 20.99 per share.D2022-05-16334.89k
Hikma Pharmaceuticals PLCBuy Back at price 20.89 per share.D2022-05-13168.46k
Hikma Pharmaceuticals PLCBuy Back at price 20.70 per share.D2022-05-12160.99k
Hikma Pharmaceuticals PLCBuy Back at price 21.38 per share.D2022-05-11291.91k
Hikma Pharmaceuticals PLCBuy Back at price 21.29 per share.D2022-05-10285.51k
Hikma Pharmaceuticals PLCBuy Back at price 21.01 per share.D2022-05-09131.74k
Hikma Pharmaceuticals PLCBuy Back at price 20.86 per share.D2022-05-06175.59k
Hikma Pharmaceuticals PLCBuy Back at price 21.01 per share.D2022-05-05242.65k
Hikma Pharmaceuticals PLCD2022-05-04
Hikma Pharmaceuticals PLCBuy Back at price 23.56 per share.D2022-05-03166.96k
Hikma Pharmaceuticals PLCBuy Back at price 23.85 per share.D2022-04-2977.85k
Hikma Pharmaceuticals PLCBuy Back at price 25.19 per share.D2022-04-2862.98k
Hikma Pharmaceuticals PLCBuy Back at price 24.82 per share.D2022-04-2793.32k
Hikma Pharmaceuticals PLCBuy Back at price 25.55 per share.D2022-04-2638.26k
Hikma Pharmaceuticals PLCBuy Back at price 25.75 per share.D2022-04-2577.01k
Hikma Pharmaceuticals PLCBuy Back at price 26.11 per share.D2022-04-2262.04k
Hikma Pharmaceuticals PLCBuy Back at price 26.50 per share.D2022-04-2159.29k
Hikma Pharmaceuticals PLCBuy Back at price 26.84 per share.D2022-04-2060.27k
Hikma Pharmaceuticals PLCBuy Back at price 26.79 per share.D2022-04-1962.14k
Hikma Pharmaceuticals PLCBuy Back at price 27.21 per share.D2022-04-1451.81k
Hikma Pharmaceuticals PLCBuy Back at price 27.17 per share.D2022-04-1335.24k
Hikma Pharmaceuticals PLCBuy Back at price 26.72 per share.D2022-04-1238.08k
Hikma Pharmaceuticals PLCBuy Back at price 27.05 per share.D2022-04-1136.59k
Hikma Pharmaceuticals PLCBuy Back at price 26.70 per share.D2022-04-0842.95k
Hikma Pharmaceuticals PLCBuy Back at price 26.71 per share.D2022-04-0750k
Hikma Pharmaceuticals PLCBuy Back at price 27.00 per share.D2022-04-0520k
Hikma Pharmaceuticals PLCBuy Back at price 27.14 per share.D2022-04-04137k
Hikma Pharmaceuticals PLCBuy Back at price 26.79 per share.D2022-04-01143.1k
Hikma Pharmaceuticals PLCBuy Back at price 27.32 per share.D2022-03-31249.62k
Hikma Pharmaceuticals PLCBuy Back at price 27.04 per share.D2022-03-30160.4k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Here is the result of two systematic investment strategies applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the equity curve of the two systematic investment strategies applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 10.83% on the backtest period.

Performance at glance

Performance

10.83 %

Latent gain

1843.5 £

Invested capital

17020.5 £

Annualized return

2.63 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

This is the result of two momentum investment strategies applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows all the entries opened by the momentum investment system on HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P momentum entries
  • The first momentum investment strategy would give 68.54% of return on HIKMA PHARMACEUTICALS PLC ORD SHS 10P. That represents 6712.4£ of latent gain with 9793.6£ of employed capital.
  • The second momentum investment strategy would give 45.24% of return on HIKMA PHARMACEUTICALS PLC ORD SHS 10P. That represents 3672.5£ of latent gain with 8117.5£ of employed capital.
Performance at glance (1Q Momentum)

Performance

68.54 %

Latent gain

6712.4 £

Invested capital

9793.6 £

Annualized return

12.67 %
Performance at glance (2Q Momentum)

Performance

45.24 %

Latent gain

3672.5 £

Invested capital

8117.5 £

Annualized return

12.43 %

Momentum equity curve on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the equity curve of the two momentum strategies applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P momentum equity

Note: the dividends potentially given by HIKMA PHARMACEUTICALS PLC ORD SHS 10P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the employed capital evolution of the two momentum strategies on HIKMA PHARMACEUTICALS PLC ORD SHS 10P since the beginning:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Buy the dip entry openings on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The performance achieved by the robo-advisor on HIKMA PHARMACEUTICALS PLC ORD SHS 10P is 26.87%. That represents 1498.0$ of latent gain with 5576.0£ of employed capital. The following chart shows HIKMA PHARMACEUTICALS PLC ORD SHS 10P stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of HIKMA PHARMACEUTICALS PLC ORD SHS 10P, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

26.87 %

Latent gain

1498.0 £

Invested capital

5576.0 £

Annualized return

12.67 %

Equity curve of the strategy applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the result of the investment strategy applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Note: the dividends potentially given by HIKMA PHARMACEUTICALS PLC ORD SHS 10P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the employed capital evolution since the beginning of the investment strategy on HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

In this section, I will compare the three previous investment strategies applied to HIKMA PHARMACEUTICALS PLC ORD SHS 10P.

Equity curve comparison on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

HIKMA PHARMACEUTICALS PLC ORD SHS 10P investment strategy comparison

Employed capital comparison on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

HIKMA PHARMACEUTICALS PLC ORD SHS 10P investment comparison

Performance comparison on HIKMA PHARMACEUTICALS PLC ORD SHS 10P

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 10.83% 1843.5£ 17020.5£ 2.63%
Momentum 1 quarter 68.54% 6712.4£ 9793.6£ 17.66%
Momentum 2 quarters 45.24% 3672.5£ 8117.5£ 12.43%
Non-directional 26.87% 1498.0£ 5576.0£ 12.67%
Annualized return comparison

Automatic investment

2.63 %

Momentum 1Q

12.43 %

Momentum 2Q

12.43 %

Non-directional

12.67 %

Correlated stocks

Here are the most positively and negatively correlated stocks with HIKMA PHARMACEUTICALS PLC ORD SHS 10P:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between HIKMA PHARMACEUTICALS PLC ORD SHS 10P and the other stocks. There may be false positives or some missing correlated stocks. If the price of HIKMA PHARMACEUTICALS PLC ORD SHS 10P does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name HIKMA PHARMACEUTICALS PLC ORD SHS 10P
Country United Kingdom
City London
Address 1 New Burlington Place
Phone 44 20 7399 2760
Website www.hikma.com
FullTime employees 8700
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XLON
Ticker HIK.XLON
Market www.londonstockexchange.com

HIKMA PHARMACEUTICALS PLC ORD SHS 10P ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 3.6
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 16.9
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 1
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer IncidentsSociety & Community IncidentsBusiness Ethics Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 8.7
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 29.2
Environment Score: 3.6
Social Score: 16.9
Governance Score: 8.7

ESG Performance: AVG_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 60